Zobrazeno 1 - 10 of 85 pro vyhledávání: '"Hsieh, Candace"'
1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
5
952 Phase II trial of AV-GBM-1: dendritic cell vaccine pulsed with lysate enriched for autologous tumor-initiating cell antigens in the treatment of patients with newly diagnosed glioblastoma
Autor: Bota, Daniela, Piccioni, David, Duma, Christopher, LaRocca, Renato, Kesari, Santosh, Abedi, Mehrdad, Carrillo, Jose, Aiken, Robert, Hsu, Frank, Kong, Xiaotang, Taylor, Thomas, Hsieh, Candace, Nistor, Gabriel, Dillman, Robert
Publikováno v: Journal for ImmunoTherapy of Cancer, vol 9, iss Suppl 2
Background: Standard therapy of glioblastoma (GBM), which includes maximum safe resection, concurrent radiation therapy and temozolomide chemotherapy (RT/TMZ) followed by maintenance TMZ, is associated with poor overall survival (OS). Adding treatmen
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::ec0b896653cb8e890d7e854dad85940f
https://escholarship.org/uc/item/6ws2q8m3
Zobrazit plný text záznamu
6
335 Leukaphereses to obtain monocytes to produce dendritic cells in manufacturing of personal autologous AV-GBM-1 vaccines in a phase II trial in patients with newly diagnosed glioblastoma
Autor: LaRocca, Renato, Bota, Daniela, Piccione, David, Duma, Christopher, Kesari, Santosh, Carrillo, Jose, Kong, Xiang-Tang, Hsu, Frank, Aiken, Robert, Abedi, Mehrdad, Taylor, Thomas, Hsieh, Candace, Nistor, Gabriel, Dillman, Robert
Publikováno v: Journal for ImmunoTherapy of Cancer, vol 9, iss Suppl 2
BackgroundFor patients with newly diagnosed primary glioblastoma (GBM), maximum safe surgical resection, concurrent radiation therapy and temozolomide chemotherapy (RT/TMZ) followed by maintenance TMZ results in a 2-year survival of only 25%. Adding
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::7cb1ed831da05795e5b80fb59c4a9428
https://escholarship.org/uc/item/99m953w8
Zobrazit plný text záznamu
7
336 Adverse events in a phase II trial of AV-GBM-1: dendritic cell vaccine pulsed with lysate enriched for autologous tumor-initiating cell antigens for patients with newly diagnosed glioblastoma
Autor: Piccioni, David, Bota, Daniela, LaRocca, Renato, Kesari, Santosh, Carillo, Jose, Kong, Xiao-Tang, Duma, Christopher, Abedi, Mehrdad, Aiken, Robert, Taylor, Thomas, Hsieh, Candace, Nistor, Gabriel, Dillman, Robert
Publikováno v: Journal for ImmunoTherapy of Cancer, vol 9, iss Suppl 2
BackgroundStandard glioblastoma (GBM) therapy includes maximum safe resection, concurrent radiation therapy and temozolomide chemotherapy (RT/TMZ), and maintenance TMZ, but it is associated with a 2-year survival of only about 25%. Adding treatment w
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::0a12cf95d5eacfa8511c2288d4791e13
https://escholarship.org/uc/item/0h30h1s2
Zobrazit plný text záznamu
8
333 Changes in proteomic markers after injections of personal AV-GBM-1 dendritic cell/tumor initiating cell vaccines in a phase II trial in patients with newly diagnosed glioblastoma
Autor: Kesari, Santosh, Bota, Daniela, Piccioni, David, Duma, Christopher, LaRocca, Renato, Kong, Xiao-Tang, Hsu, Frank, Carrillo, Jose, Abedi, Mehrdad, Aiken, Robert, Taylor, Thomas, Poole, Aleksandra, Hsieh, Candace, Nistor, Gabriel, Dillman, Robert
Publikováno v: Journal for ImmunoTherapy of Cancer, vol 9, iss Suppl 2
Background: Despite standard aggressive therapy, including maximum safe surgical resection, concurrent radiation therapy and temozolomide chemotherapy (RT/TMZ) followed by maintenance TMZ, survival is still extremely poor for patients with newly diag
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::f202fcb3f4c383a77829fd674f30e03d
https://escholarship.org/uc/item/3v8686ts
Zobrazit plný text záznamu
9
331 Tumor markers associated with increased survival in a phase II trial of dendritic cell/tumor-initiating-cell vaccine AV-GBM-1 in patients with newly diagnosed glioblastoma
Autor: Bota, Daniela, Piccioni, David, Duma, Christopher, LaRocca, Renato, Kesari, Santosh, Carrillo, Jose, Hsu, Frank, Kong, Xiao-Tang, Abedi, Mehrdad, Aiken, Robert, Taylor, Thomas, Hsieh, Candace, Nistor, Gabriel, Dillman, Robert
Publikováno v: Journal for ImmunoTherapy of Cancer, vol 9, iss Suppl 2
Background: Standard aggressive therapy of glioblastoma (GBM), which includes maximum safe resection, concurrent radiation therapy and temozolomide chemotherapy (RT/TMZ) followed by maintenance TMZ, is associated with a 25% 2-year overall survival (O
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::7d8706d2cb14e259bd1fa7583d582a98
https://escholarship.org/uc/item/1453h6z8
Zobrazit plný text záznamu
10
332 Tumor collection and establishment of tumor-initiating cell cultures as antigen source for AV-GBM-1 dendritic cell vaccines for a phase II trial in patients with newly diagnosed glioblastoma
Autor: Duma, Christopher, Bota, Daniela, Hsu, Frank, Piccioni, David, LaRocca, Renato, Kesari, Santosh, Abedi, Mehrdad, Carrillo, Jose, Aiken, Robert, Kong, Xiao-Tang, Taylor, Thomas, Hsieh, Candace, Nistor, Gabriel, Dillman, Robert
Publikováno v: Journal for ImmunoTherapy of Cancer, vol 9, iss Suppl 2
BackgroundDespite standard aggressive therapy (maximum safe surgical resection, concurrent radiation therapy and temozolomide chemotherapy (RT/TMZ), then maintenance TMZ), 2-year survival is only about 25% for patients with newly diagnosed primary gl
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::42dc07398f123646650bb6b08e056082
https://escholarship.org/uc/item/2vf8x8v2
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje